The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.

Research 40

Research Clinical Trials Small Molecule Pharmacokinetics 40

Alta Sciences

OCTOBER 30, 2023

Discover the considerations and assessments necessary for performing preclinical research for ophthalmic therapies in this new eBook, that covers everything you need to know, from species selection and routes of administration, to preparing for first-in-human trials. Watch the video. Listen here. Watch it now. The Altascientist : Issue No.

Science 52

Science Clinical Trials Pharmacokinetics Pharmacy 52

Drug Target Review

JUNE 6, 2023

Difficult-to-treat and rare, complicated cancers remain a perplexing challenge for IO researchers. Research has shown that these immune system proteins have the ability to trigger anti-cancer immune pathways. Clinical development of IL-18 therapies has been curtailed, however, by the protein’s lack of efficacy.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

Advarra

JUNE 20, 2023

According to a 10-year oncology research study conducted by the Biotechnology Innovation Organization (BIO), only 5.1% Additionally, in 2021, a literature review estimated the average capitalized research and development (R&D) costs per new cancer medicine at between $944 million and $4.54

Trials 52

Trials Clinical Trials FDA Approval Animal Testing 52

PerkinElmer

JANUARY 7, 2022

The pharmaceutical industry is under huge pressure to address the high attrition rates in drug development. With around 90% of candidates failing during clinical development, 1 the process is not only long and risky, but also expensive for those involved.

Drugs 52

Drugs Pharmacokinetics FDA Approval Drug Development 52

Sygnature Discovery

NOVEMBER 29, 2023

QN-302 has been conceived to work by selectively stabilizing G-quadruplex complexes prevalent in the promoter region of cancer-related genes in many tumor types, impeding the function of these cancer genes, and may therefore potentially offer a tumor-selective clinical approach to treatment. Qualigen Therapeutics’ Chief Medical Officer.

Clinical Trials 52

Clinical Trials Treatment Trials Small Molecule 52

PPD

MAY 11, 2023

The speed at which COVID-19 vaccines were developed was remarkable, but like most newly developed vaccines, there was variation among who could receive the shots and when. Sharing information about the research, including risk and benefits, tailored to the patient’s level of understanding.

Vaccine 52

Vaccine Clinical Trials Long-Term Care Facilities Trials 52

The Pharma Data

OCTOBER 27, 2020

AavantiBio’s strategic partnership with University of Florida’s Powell Gene Therapy Center provide their foundational research in rare genetic disorders. Sirnaomics is the only biopharma conducting R&D and clinical development in the field of RNAi therapeutics in both the U.S. The company’s $27.4 Source link.

Small Molecule 52

Small Molecule Immune Response Pharmacokinetics Clinical Development 52

The Pharma Data

APRIL 11, 2021

The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021. Use of Retevmo for these indications is supported by evidence from adequate and well-controlled studies in adults with additional pharmacokinetic and safety data in pediatric patients aged 12 years and older.

Research 52

Research Treatment Therapies Trials 52

Sygnature Discovery

NOVEMBER 29, 2023

QN-302 has been conceived to work by selectively stabilizing G-quadruplex complexes prevalent in the promoter region of cancer-related genes in many tumor types, impeding the function of these cancer genes, and may therefore potentially offer a tumor-selective clinical approach to treatment. Qualigen Therapeutics’ Chief Medical Officer.

Clinical Trials 40

Clinical Trials Treatment Trials Small Molecule 40

The Pharma Data

DECEMBER 13, 2020

Zai Labs obtained regional development and commercialization rights for the programs in mainland China, Hong Kong, Macau and Taiwan. Zai Lab is leading clinical development in its territory. “We That collaboration was to develop and commercialize four oncology antibody biosimilar therapies. Most Read Today.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

NOVEMBER 5, 2021

About the study NCT03832114 is a Phase II, open- marker, two cohort,non-randomized study assessing the efficacity, safety and pharmacokinetics of iptacopan in cases with C3 glomerulopathy (C3G) ( cohort A) and cases who have experienced order transplantation and have posterior C3G rush in the transplanted organ ( cohort B).

Disease 52

Disease Pharmacokinetics Treatment FDA 52

The Pharma Data

NOVEMBER 9, 2021

We ’re agitated to partake data from our robust clinical development programs at AASLD’s The Liver Meeting ®, including the rearmost data demonstrating the positive impacts of bulevirtide for people living with HDV.”.

Disease 52

Disease Clinical Trials Treatment Pharmacokinetics 52

The Pharma Data

AUGUST 19, 2021

FACP, Director of the Virginia Cancer Specialists Research Institute, Co-Chair U.S. Vice President, Clinical Development, Solid Tumors, Janssen Research & Development, LLC. “We entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

JANUARY 3, 2021

With these important regulatory clearances for our first-in-human clinical trial for INZ-701 in subjects with ENPP1 deficiency, we have transitioned from a research-stage to a clinical-stage company. Exploratory objectives include obtaining baseline measurements of calcification, patient reported outcomes and quality of life.

Clinical Trials 52

Clinical Trials Trials Treatment FDA 52

The Pharma Data

NOVEMBER 8, 2020

The submission includes data from the ENLIGHTEN clinical development program in schizophrenia, and pharmacokinetic (PK) bridging data comparing ALKS 3831 and Zyprexa (olanzapine), to support an indication for schizophrenia. Reese, executive vice president of Research and Development at Amgen.

FDA 52

FDA Trials Pharmaceuticals Pharmacokinetics 52

Agency IQ

SEPTEMBER 15, 2023

The committee also made recommendations regarding pharmacokinetic and safety assessments. Of the other three comments on the Citizen Petition docket, one supportive comment came from researchers who conducted studies supportive of the petitioner’s assertion of lack of symptomatic efficacy for phenylephrine.

Science 40

Science FDA Clinical Trials Pharmacy 40

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells.

Research 130

Research Therapies Immune Response Clinical Trials 130

PPD

SEPTEMBER 19, 2023

Whichever route a company takes, deliberate decision-making around the nature and timing of early phase studies is important to manage risks in the clinical development process. Benefits of Early Drug Development Services Early development studies include many elements that set them apart from those in later development.

Clinical Trials 98

Clinical Trials Pharmacokinetics Clinical Development Drug Development 98

Drug Discovery World

DECEMBER 13, 2023

It demonstrated a differentiated in vitro activity profile across several assays compared with small molecule and antibody inhibitors of CD73 in clinical development. Cidara is currently advancing its dual CD73/PD-1 inhibitor DFC and CBO421 in preclinical studies.

Small Molecule 130

Small Molecule Biosimilars Pharmacokinetics Drugs 130

Drug Discovery World

FEBRUARY 22, 2024

With no in-house laboratory space, the company works closely with multiple international contract research organisations (CROs), including Axxam, which carry out all of the Libra R&D, from compound screening assays, to in vivo pharmacokinetic/pharmacodynamic and ADME work, as well as in vitro and in vivo pre-clinical safety assessments.

Clinical Trials 130

Clinical Trials Trials Small Molecule Compound Screening 130

Drug Discovery World

JANUARY 31, 2024

Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress. With the drug development expertise and successful track records of the Onward Therapeutics team, we have moved forward from the cell line development, scale up, 1,000-litre?

Clinical Trials 130

Clinical Trials Trials Treatment Pharmacokinetics 130

Drug Discovery World

NOVEMBER 3, 2022

VRG50635 is the only PIKfyve inhibitor in clinical development that has been specifically optimised for treatment of central nervous system disorders like ALS, and has potential for best-in-class characteristics. . We look forward to sharing the progress of our VRG50635 clinical studies and continued research in due course.” .

Trials 130

Trials Small Molecule Clinical Trials Pharmacokinetics 130

Drug Discovery World

JANUARY 4, 2024

In the study, ANX1502 achieved target serum levels and demonstrated pharmacokinetic (PK) measures that support advancement into a proof-of-concept clinical study to assess pharmacodynamics (PD) and efficacy in patients with cold agglutinin disease (CAD) in 2024.

Small Molecule 130

Small Molecule Pharmacokinetics Clinical Development Disease 130

The Pharma Data

JULY 21, 2021

These data were shared as a late-breaking oral presentation during the virtual 11 th International AIDS Society Conference on HIV Science (IAS 2021) and are a follow-up to the interim analysis that was presented earlier this year at the virtual 2021 HIV Research for Prevention Conference (HIVR4P 2021). Our Commitment to HIV.

Clinical Trials 52

Clinical Trials Pharmacokinetics Trials International 52

Drug Discovery World

APRIL 17, 2023

The Phase I clinical trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TOS-358 as a single agent in 241 trial participants with select solid tumours. The study will be conducted in two parts.

Clinical Trials 130

Clinical Trials Pharmacokinetics Trials Clinical Development 130

The Pharma Data

NOVEMBER 4, 2020

Key findings of the research showed that patients with alopecia areata suffer significantly increased burden of illness, including a negative impact on many aspects of daily life, extending considerably beyond the cosmetic concerns of hair loss. Research and development expenses were $16.3 R&D Expenses. .

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

AUGUST 29, 2020

3,4 LNP023 is currently in clinical development for PNH and a number of renal conditions with complement system involvement where significant unmet needs exist, including IgA nephropathy, complement 3 glomerulopathy (C3G), atypical hemolytic uremic syndrome and membranous nephropathy.

Treatment 52

Treatment Disease Small Molecule Production 52

Drug Discovery World

AUGUST 8, 2022

SS: The data of FRONTIER1 are encouraging and present an opportunity to develop a treatment for people with haemophilia A who may benefit from less frequent administration 1,2. ? We look forward to moving into phase 3 clinical development, which is due to commence in Q4 2022. References . 1 ClinicalTrials.gov.

Treatment 130

Treatment Clinical Trials International Disease 130

The Pharma Data

DECEMBER 5, 2020

Additionally, Regeneron bispecifics are manufactured using similar approaches used for human monoclonal antibody medicines, yielding similar properties and pharmacokinetics. REGN5458 and odronextamab are currently under clinical development, and their safety and efficacy have not been evaluated by any regulatory authority.

Production 40

Production Trials Treatment Pharmaceuticals 40

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Treatment 52

Treatment Disease Pharmaceuticals Therapies 52

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the company’s HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21. No Pharmacokinetic Interaction Between Novel NNRTI MK-8507 and Islatravir.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Treatment 52

The Pharma Data

SEPTEMBER 1, 2020

study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. Abstracts include company-sponsored and collaborative studies with academic partners such as Brigham and Women’s Hospital and Cleveland Clinic.

Clinical Trials 52

Clinical Trials Treatment Trials Disease 52

The Pharma Data

DECEMBER 13, 2020

The Phase 2b trial will also evaluate efficacy on other histology endpoints (fibrosis), assessment of metabolic and non-metabolic parameters, pharmacokinetic assessment as well as safety and tolerability. Harrison, MD, Director, Summit Clinical Research. The Phase 2b trial is expected to begin during the second half of 2021.

Trials 52

Trials Disease Treatment Pharmacokinetics 52

Drug Discovery World

DECEMBER 13, 2023

Custom antibodies can be developed for pharmacokinetic assays and biodistribution assays, supporting therapeutic development by giving researchers data about the behaviour of their novel therapeutic in vivo. Researchers can rely on Bethyl’s antibodies for their quality and reproducibility.

Science 147

Science Small Molecule Laboratories Engineering 147

The Pharma Data

APRIL 7, 2022

We’re continuing to grow our pipeline – through our own research-and-development efforts, such as our investigational RSV vaccine programs, as well as strategic investments in companies like ReViral – with a focus on end-to-end capabilities to help protect patients from severe illness, hospitalization, and death.”.

Virus 52

Virus Vaccine Clinical Development Hospitals 52

The Pharma Data

DECEMBER 21, 2020

Phase I safety, tolerability, and pharmacokinetic study in healthy volunteers expected to start in coming weeks following acceptance of a request for a Clinical Trial Authorization (CTA) granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA). ALLSCHWIL, Switzerland, Dec.

Clinical Trials 40

Clinical Trials Trials Pharmacokinetics Clinical Development 40